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ABSTRACT  
Activation of the endothelium is a pivotal first step for leukocyte migration into the diseased 
brain. Consequently, imaging this activation process is highly desirable. We synthesized 
carbohydrate-functionalized magnetic nanoparticles that bind specifically to the endothelial 
transmembrane inflammatory proteins E and P selectin. Magnetic resonance imaging revealed 
that the targeted nanoparticles accumulated in the brain vasculature following acute 
administration into a clinically relevant animal model of stroke, though increases in selectin 
expression were observed in both brain hemispheres. Non-functionalized naked particles also 
appear to be a plausible agent to target the ischemic vasculature. The importance of these 
findings is discussed regarding the potential for translation into the clinic. 
 
Inflammation plays a major role in neurological disorders such as stroke, and the ability 
to image inflammatory processes would provide valuable information to aid patient 
stratification, and eventually treatment. Magnetic resonance imaging (MRI) is being used 
increasingly as a diagnostic tool in the acute stroke setting, and several contrast agents are 
approved to analyze the injured brain for blood brain barrier breakdown or vascularization. 
Magnetic nanoparticles (MNPs), especially iron oxide Fe3O4-MNPs, have been widely used as 
biosensors owing to their relatively low toxicity.1-5 Some MNP formulations are potential 
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imaging agents for the inflammatory response to stroke, particularly the blood borne 
leukocytes.6 However, lack of blood brain barrier penetrability and relatively poor 
inflammatory cell uptake has remained an obstacle.7, 8 Therefore, the identification and 
specific targeting of accessible inflammatory components, for example, the endothelium, is 
highly attractive. E and P selectin (CD62E and P, respectively) are endothelial transmembrane 
proteins that participate in leukocyte adherence to blood vessels during inflammation.9 E and 
P selectin are generally thought to be pro-inflammatory, and thus detrimental to stroke 
outcome, hence, they have been suggested as potential imaging targets.10 For selectin binding, 
MNPs have been functionalized with peptides5 and carbohydrates such as Sialyl LewisX 
(SX).1 Carbohydrate-functionalized MNPs can take advantage of clustering effects to achieve 
high binding affinities and specificities when compared to monovalent carbohydrate–protein 
interactions.11-13 Several glyco-functionalized nanoparticles (NPs) with high surface to volume 
ratios have been reported to be good multivalent carriers of carbohydrate ligands that bind 
with high affinity to the targeted receptors.14-19 We designed silica coated iron oxide core shell 
MNPs, which exhibit superparamagnetism and strong saturation magnetism, and also lend 
themselves to carbohydrate functionalization.4, 15 The silica outer shell provides excellent 
stability and protection of the magnetic core, thus avoiding oxidative stress to cells.2, 20 
The known E and P selectin ligand sialyl Lewisx (SX, 1) was immobilized on silica iron 
oxide nanoparticles (SX@MNPs) to target these proteins that are believed to be expressed on 
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activated vascular endothelial cell as a result of inflammation. The interactions between the 
selectins and SX-glycoconjugate ligands play key roles in adhesive interaction among these 
inflamed vascular surfaces. As non-targeting controls for targeting experiments using 
SX@MNPs, nanoparticles carrying the carbohydrate LewisX (LX, 2) (LX@MNP) or simple 
hydroxy groups (HO@MNPs) were designed. The three different MNP formulations were 
administered to mice that underwent transient middle cerebral artery occlusion (MCAO), 
which is a clinically relevant animal model of stroke with a strong inflammatory component.  
Amino-functionalized silica iron oxide core shell nanoparticles (NH2@MNPs) with a 
diameter of 18 nm (Figure 1a) were prepared as described.15 NH2@MNPs were then reacted 
with succinic anhydride under basic conditions at room temperature overnight to afford 
carboxylic acid modified nanoparticles (COOH@MNPs, Scheme 1). Activation of the 
carboxylic acid groups on the surface of the COOH@MNPs was accomplished using NHS 
and EDC to yield N-hydroxysuccinimide activated MNPs (NHS@MNPs). After removing 
excess reagents, LX21 and SX22 were immediately added to the NHS@MNPs in DMF and 
NEt3 at room temperature for 48 h. LX 1 and SX 2 were prepared using an automated 
solid-phase oligosaccharide synthesizer21, 22 (NMR spectra see Figures S1 and S2). Following 
amide bond formation, the solvent was removed by magnetic separation and the remaining 
NHS groups on the MNPs were capped with ethanolamine to afford carbohydrate decorated 
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MNPs (LX@MNPs and SX@MNPs, respectively). In a similar manner HO@MNPs were 
prepared by quenching the NHS-groups without the addition of carbohydrates.  
 
Scheme 1. Synthesis of HO@MNPs and carbohydrate@MNPs (LX@MNPs and 
SX@MNPs). 
 
 
All MNP formulations were characterized by the zeta potential for their surface charge 
(Figure 1b) and dynamic light scattering (DLS) for their hydrodynamic diameter (Figure S3 
and Table S1). The zeta-potential measurements (Figure 1b) provided valuable information 
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about the success of each reaction step. Intensity-weighted hydrodynamic diameters were 
found to be between 120 and 160 nm and the polydispersity indexes were between 0.17 and 
0.22. The amount of SX present on the SX@MNPs was estimated using a SialicQ 
quantification kit (Figure S4). This enzymatic method can detect the efficiency of sialic acid 
incorporation and can be accurately measured using spectrophotometry. Levels of Sialyl 
LewisX in the SX@MNPs were determined to be at 10.5 ± 1.2 nmol•mg-1, corresponding to 
around 30% coupling yield over three reaction steps based on the density of the amines in 
NH2@MNPs.15 Binding specificity of the SX@MNPs to rat E-Selectin was tested in vitro 
using a spectrophotometric binding method (Figures 1c and S5) and SX@MNPs resulted in 
the strongest binding to the E-selectin-Fc chimera protein.  
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Figure 1. (a) TEM image of NH2@MNPs. (b) Zeta-potential of the particle formulations 
indicating overall charge (NUMBER OF SAMPLES). (c) Specific binding assay of each 
MNP formulation to rat E-selectin in vitro (NUMBER OF SAMPLES).  
 
Following extensive MNP characterization, we randomly administered one of the 
three formulations (HO@MNPs, LX@MNPs, or SX@MNPs) to mice 5.5 h after they 
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underwent the most common animal model of stroke: transient MCAO via the intraluminal 
filament technique (Supplementary Methods). A transient model of MCAO was chosen 
because reperfusion occurs frequently in the patient population. Furthermore, transient models 
reduce the risk of intravascular trapping of contrast agents in situations of low flow that are 
produced with permanent models. The intraluminal filament technique offers the additional 
advantage of not challenging the endothelium of the middle cerebral artery (MCA) as would 
be the case with vasoconstrictors. T2* weighted sequences were chosen to identify the MNPs 
as they are extremely sensitive to susceptibility effects. A T2* weighted sequence was 
acquired just prior to MNP administration (5 h post MCAO) to exclude the presence of 
pre-existing microbleeds and/or endogenous sources of negative contrast. The sequence was 
repeated immediately after intravenous MNP administration to detect blood pool effects, and 
again at 24 h post MCAO to observe vascular accumulation. Massive blood pool effects were 
observed following administration of all MNP formulations in the T2* weighted images, 
which were no longer present at 24 h. However, at this time, numerous punctate regions of 
signal loss were observed in the brains of all animals (Figure 2). 
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Figure 2. T2 maps and T2* weighted images at 5 and 24 h after MCAO in a representative 
animal that received (a) HO@MNPs (n=5), (b) LX@MNPs (n=6), or (c) SX@MNPs (n=5). 
Note: the color scale bar corresponds to the T2 value (ms). 
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T2 maps and T1 weighted images were acquired in parallel to the T2* weighted images. T2 
maps detect and quantify ischemic damage that is only beginning to develop at 5 h post 
MCAO and is maximal at 24 h. There were no differences in infarct sizes among the groups at 
either time point (5 or 24 h post MCAO), indicating comparable levels of pathology among 
the animals. The ischemic tissue is not visible with T1 weighting, thus making it easier to 
observe relaxivity changes due to the MNPs. However, the effects were most pronounced, as 
anticipated, in the T2* weighted images. 
 
To confirm which groups exhibited the greatest accumulation of MNPs at 24 h post 
MCAO, the number of punctate regions of signal loss were counted in the entire brain, as well 
as within the ischemic territory and the corresponding region mirrored to the contralateral 
hemisphere (Figure 3). 
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Figure 3. a) The total number of dark voxels in the brains of the animals from each group: 
HO@MNPs (n=5), LX@MNPs (n=6), and SX@MNPs (n=5). b) The number of dark voxels 
in the infarcted tissue expressed as a ratio of the mirrored contralateral region. c) The amount 
of CD62E expression (in relation to sham animals (n=3)) in the ipsi- and contralateral 
hemispheres of mice with either 5 (n=4) or 24 h (n=4) of MCAO. 
 
There was a significant and robust main effect of group (F(2,13) 4.536, p= 0.03; ω2= 0.1; 
one way ANOVA) when the total number of dark voxels across the entire brain was compared 
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(Figure 3a). The largest number of dark voxels overall in the brain were observed in the 
SX@MNP treated group and the lowest number in the LX@MNP group (p= 0.036, post-hoc 
comparison; d= 2.167) (Figure 3a). However, even though there were more dark spots in the 
SX@MNP treated group, the difference between this group and the HO@MNP treated group 
failed to reach significance. These in vivo observations partially support the in vitro binding 
specificity results in that SX@MNPs are more abundant when compared to the 
non-functionalized LX@MNP control particles, but not the HO@MNP particles.  
 
There was also a significant and robust main effect of group F(2,13) 5.997, p= 0.014; 
ω2= 0.2; one way ANOVA) when the number of dark voxels (expressed as a ratio between 
the ischemic tissue and the corresponding mirrored region in the intact side of the brain) was 
compared (Figure 3b). The highest ratio was observed in the HO@MNP treated group, while 
the lowest ratio was observed in the SX@MNP group (p= 0.013, post-hoc comparison; d= 
2.215) (Figure 3b). This may be partially explained by the fact that there were two animals in 
the HO@MNP treated group that exhibited large regions of signal loss at 24 h in the ischemic 
territory (Figure S6) that we have not seen with a variety of other non-functionalized MNPs.7 
HO@MNPs may therefore be prone to accumulation in the ischemic territory irrespective of 
selectin expression. It is possible that there is an unknown factor in the in vivo 
microenvironment that is responsible for this, or that the surface polarity of these particles 
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differs. Indeed, a comparison of the three particles indicates that HO@MNPs are less polar. 
On the other hand, the lack of an increased number of dark spots in the ischemic tissue of the 
SX@MNP treated group suggests that increases in selectin expression may not be confined to 
the injured tissue, a phenomenon we confirmed independently using a Western blot to 
semi-quantify CD62E expression in the ischemic and contralateral hemispheres of mice that 
underwent MCAO. At 5 h post MCAO, there was only a slight increase in CD62E expression 
in the ischemic hemisphere, which was not significant (Figure 3c). By 24 h, selectin 
expression in the contralateral hemisphere was still comparable to that of the contralateral 
hemisphere at 5 h. However, CD62E expression was lower in the ipsilateral hemisphere, 
which is likely explained by the extensive damage incurred to the ischemic tissue by 24 h. 
However, this decrease was still not significantly different from the expression in the 
contralateral side. These findings are not completely unexpected as increased selectin 
expression in the intact hemisphere following MCAO has been reported.23 Indeed, stroke is 
also a systemic disease with upregulation of the peripheral inflammatory system and blood 
borne pro-inflammatory mediators that have widespread effects. 
To exclude the possibility that the MNPs were entering the brain parenchyma rather 
than accumulating in the blood vessels, brain tissue was extracted and stained with Prussian 
blue to detect the presence of iron (Figure 4). 
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Figure 4. a) Prussian blue staining in blood vessels in the ischemic territory of an animal 
treated with HO@MNPs. b) High amounts of iron were detected in the spleen and c) liver. 
Prussian blue staining confirmed that most of the iron was found in the spleen (Figure 4b) and 
liver (Figure 4c) of the animals in all three treatment groups. Iron was not detected in the 
brains of any of the animals, which implies that binding or accumulation in the blood vessels 
was disrupted during tissue preparation, likely due to the saline perfusion. However, a small 
amount of iron was identified in the ischemic region of a single animal that received 
HO@MNPs (Figure 4a). In this animal, we confirmed that the MNPs were confined to the 
blood vessels and not the parenchyma (Figure 4a inset).  
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In conclusion, we investigated the ability of SX@MNPs to target E and P selectin in 
the ischemic brain. While the specificity of these particles appears to be high for the target, 
selectin expression is up-regulated over the entire brain, and not only in the ischemic tissue. 
Interestingly, when appropriate control particles are employed, HO@MNPs appear to be best 
at accumulating in the injured blood vessels. This highlights both the inherent challenges that 
arise from in vivo work with increasingly complicated models and the utility of appropriate 
control experiments. Caution is therefore urged during interpretation on account of the 
variability. As the employed MRI sequences can be easily applied in the clinic, these results 
are at the forefront of translation moving towards non-invasive imaging of the activated 
endothelium in a patient population.  
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